Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study

The widespread use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes and obesity has prompted investigation into their dermatologic side effects, including hair loss.1 Prior studies have associated semaglutide and tirzepatide with potential hair loss.2-4 This retrospective population-based cohort study used TriNetX, a multicenter database of de-identified electronic medical records, to evaluate whether patients treated with semaglutide and tirzepatide developed new-onset hair loss.